In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...

Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...

CENTRAL TRUST Co lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.7% in ...

REGNERON'S eighth annual “Day for Doing Good” was marked in Limerick and all over the world. It is a global volunteerism ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Regeneron’s annual “Day for Doing Good,” running from October 18-24, sees over 1,000 employees in Limerick join the company’s ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.